Trick and treat: Ambushing recurrent tumors before they get out of the door

Nicolas Boisgerault; Richard G. Vile

Trick and treat: Ambushing recurrent tumors before they get out of the door

Molecular Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Monitoring and treating dormant tumors represents a major clinical challenge. We have recently found that early recurring tumors elicit an innate immune response that can be detected systemically. We also demonstrated that it may be possible to target minimal residual disease before or after immune evasion with carefully timed, rational therapeutic approaches.

Original language	English (US)
Article number	e27811
Journal	OncoImmunology
Volume	3
Issue number	1
State	Published - Jan 1 2014

Keywords

Innate immune response
Minimum residual disease
Tumor dormancy
Tumor recurrence
VEGF

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

Cite this

@article{8126fc70b8784b9ca30ac83f68cca706,

title = "Trick and treat: Ambushing recurrent tumors before they get out of the door",

abstract = "Monitoring and treating dormant tumors represents a major clinical challenge. We have recently found that early recurring tumors elicit an innate immune response that can be detected systemically. We also demonstrated that it may be possible to target minimal residual disease before or after immune evasion with carefully timed, rational therapeutic approaches.",

keywords = "Innate immune response, Minimum residual disease, Tumor dormancy, Tumor recurrence, VEGF",

author = "Nicolas Boisgerault and Vile, {Richard G.}",

year = "2014",

month = jan,

day = "1",

language = "English (US)",

volume = "3",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "1",

}

TY - JOUR

T1 - Trick and treat

T2 - Ambushing recurrent tumors before they get out of the door

AU - Boisgerault, Nicolas

AU - Vile, Richard G.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Monitoring and treating dormant tumors represents a major clinical challenge. We have recently found that early recurring tumors elicit an innate immune response that can be detected systemically. We also demonstrated that it may be possible to target minimal residual disease before or after immune evasion with carefully timed, rational therapeutic approaches.

AB - Monitoring and treating dormant tumors represents a major clinical challenge. We have recently found that early recurring tumors elicit an innate immune response that can be detected systemically. We also demonstrated that it may be possible to target minimal residual disease before or after immune evasion with carefully timed, rational therapeutic approaches.

KW - Innate immune response

KW - Minimum residual disease

KW - Tumor dormancy

KW - Tumor recurrence

KW - VEGF

UR - http://www.scopus.com/inward/record.url?scp=84899089801&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899089801&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84899089801

SN - 2162-4011

VL - 3

JO - OncoImmunology

JF - OncoImmunology

IS - 1

M1 - e27811

ER -

Trick and treat: Ambushing recurrent tumors before they get out of the door

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this